Akums Drugs and Pharmaceuticals share price
NSE: AKUMSBSE: 544222Pharmaceuticals & BiotechnologySmall Cap
Last close ₹669.00down ₹11.20 (1.65%)BSE ₹668.10
Share price at the NSE close on 23 Oct 2026. Previous close ₹680.20.
52-week range of traded prices to 23 Oct 2026
₹409.30Low, 21 Jan 2026₹838.80High, 23 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹10,530 Cr630th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 8 Aug 2026
- 36.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 14 May 2026
- 3.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.45%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 8 Aug 2026
- 9.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 8 Aug 2026
- 12.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 14 May 2026
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,89,38152.3% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 8 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹1,167 Crup 0.76%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹101 Crup 24.14%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 8.7%
Revenue by year
Peak revenue ₹4,359 Cr, year to Mar 2026
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 9 Nov | Dec 2024Filed 6 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 8 Aug | Sep 2025Filed 13 Nov | Dec 2025Filed 13 Feb | Mar 2026Filed 14 May | Jun 2026Filed 8 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,033 | 1,010 | 1,056 | 1,024 | 1,018 | 1,160 | 1,158 | 1,167 |
| Net profit | 67 | 66 | 150 | 65 | 43 | 68 | 81 | 101 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 6.5% | 6.6% | 14.2% | 6.3% | 4.2% | 5.8% | 7.0% | 8.7% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- CDMOCDMO, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹3,485 Crup 8.65%80.0%
- Domestic Branded FormulationsDomestic Branded Formulations, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹446 Crup 2.93%10.2%
- APIAPI, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹184 Crdown 15.90%4.2%
- International Branded FormulationsInternational Branded Formulations, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹143 Crup 0.60%3.3%
- Trade GenericsTrade Generics, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹100 Crdown 13.21%2.3%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 62% of 247 trading days over the last year.
LowestHighest
Its median26.6Industry median28.1
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 74% of 247 trading days over the last year.
LowestHighest
Its median2.5Industry median2.8
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.15.7
At or below today's level on 68% of 247 trading days over the last year.
LowestHighest
Its median14.2Industry median18.7
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 98% of 550 trading days since Aug 2024.
LowestHighest
Its median0.00%Industry median0.53%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −0.9% | −22.4% | +27.0% | 0.6% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1 year is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Mutual funds holding it
21 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 8 of the 12 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 1
- AddedAdded. Funds that held more shares than at the end of the month before.
- 5
- CutCut. Funds that held fewer shares than at the end of the month before.
- 7
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 8
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 1
| Fund | |||
|---|---|---|---|
 Franklin India Opportunities FundFranklin Templeton Mutual Fund | 25,33,367 | 2.17% | ₹207.4 Cr |
| Franklin India Small Cap FundFranklin Templeton Mutual Fund | 21,17,232 | 1.22% | ₹173.3 Cr |
 Bandhan Small Cap FundBandhan Mutual Fund | 17,73,851 | 0.40% | ₹145.2 Cr |
 ICICI Prudential Healthcare FundICICI Prudential Mutual Fund | 16,04,863 | 1.91% | ₹131.4 Cr |
 Nippon India Pharma FundNippon India Mutual Fund | 13,51,672 | 1.21% | ₹110.6 Cr |
| Franklin India Multi Cap FundFranklin Templeton Mutual Fund | 10,42,859 | 1.67% | ₹85.4 Cr |
| Templeton India Value FundFranklin Templeton Mutual Fund | 4,50,000 | 2.04% | ₹36.8 Cr |
 Old Bridge Flexi Cap FundOld Bridge Mutual Fund | 1,54,000 | 2.80% | ₹12.6 Cr |
 JioBlackRock Flexi Cap FundJio BlackRock Mutual Fund | 1,08,715 | 0.28% | ₹8.90 Cr |
 Motilal Oswal Nifty Microcap 250 Index FundMotilal Oswal Mutual Fund | 94,021 | 0.32% | ₹7.70 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Akums Drugs and Pharmaceuticals in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Alembic PharmaceuticalsAPLLTD | 14,941 | 21.6 | 2.6 | 13.8 | +14.1% | +14.6% | 12.7% | 11.8% | 1.58% |
 Marksans PharmaMARKSANS | 13,001 | 25.2 | 4.3 | 16.9 | – | – | 17.1% | 19.9% | 0.31% |
 Concord BiotechCONCORDBIO | 12,860 | 46.7 | 6.4 | 33.1 | −6.7% | −22.7% | 14.4% | 15.6% | 0.61% |
 CORONA RemediesCORONA | 12,545 | 63.0 | 16.8 | 39.9 | – | – | 26.6% | 30.9% | 0.49% |
 Strides Pharma ScienceSTAR | 9,354 | 15.2 | 3.0 | 11.5 | +7.3% | – | 21.7% | 15.1% | 0.49% |
 Viyash ScientificVIYASH | 9,017 | – | 3.1 | 15.5 | +96.5% | – | – | 11.2% | 0.00% |
 Blue Jet HealthcareBLUEJET | 9,001 | 38.3 | – | – | −27.5% | −34.5% | 18.8% | 18.1% | 0.25% |
 Procter & Gamble HealthPGHL | 8,325 | 23.3 | 15.9 | 17.5 | – | – | 67.2% | 84.2% | 4.09% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.Highest ₹3.00 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 3 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.00 |
| 3 Jul 2026 | Special | ₹2.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
15 Oct · Legal
Sep 2026
23 Sep · Analysts
16 Sep · Analysts
3 Sep · General Updates
Aug 2026
25 Aug · Analysts
Akums Drugs and Pharmaceuticals share price by year
Each calendar year to 2025.Akums Drugs and Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 453.40 | −29.0% | 641.25 | 414.05 |
| 2024 | 638.40 | – | 1,119.95 | 553.00 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2024 is from its first session, 6 Aug 2024.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 676.00 | 679.45 | 663.00 | 669.00 | 670.42 | 1,89,381 | 52.3% |
| 22 Oct 2026 | 680.10 | 695.25 | 675.00 | 680.20 | 685.33 | 3,02,529 | 50.5% |
| 21 Oct 2026 | 708.00 | 719.35 | 685.00 | 694.05 | 695.70 | 4,13,633 | 61.3% |
| 19 Oct 2026 | 731.45 | 739.40 | 704.50 | 709.55 | 716.21 | 4,95,675 | 61.2% |
| 16 Oct 2026 | 749.80 | 752.80 | 728.70 | 731.45 | 735.96 | 1,50,744 | 51.8% |
| 15 Oct 2026 | 769.95 | 769.95 | 743.20 | 749.80 | 752.53 | 1,24,399 | 55.7% |
| 14 Oct 2026 | 773.95 | 776.00 | 753.30 | 769.95 | 763.92 | 1,34,294 | 50.4% |
| 13 Oct 2026 | 746.10 | 774.55 | 735.00 | 769.30 | 752.92 | 1,33,957 | 48.1% |
| 12 Oct 2026 | 750.00 | 774.65 | 749.30 | 751.45 | 756.51 | 1,77,015 | 55.2% |
| 9 Oct 2026 | 780.80 | 791.90 | 740.80 | 751.85 | 759.83 | 4,38,753 | 44.4% |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Akums Drugs and Pharmaceuticals Limited
- NSE symbol
- AKUMS
- BSE code
- 544222
- ISIN
- INE09XN01023
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Aug 2024
- Face value
- ₹2
- CIN
- L24239DL2004PLC125888
- Corporate identity number, the registrar of companies' code for it